HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dentek Destocking Takes Bite Off Prestige Topline Despite Brand-Building

Executive Summary

Dentek oral care brand struggles with retailer destocking as Prestige Consumer Healthcare continues brand-building including working with retailers to expand inventory and running TV campaigns on nighttime teeth grinding. Firm reports net sells fell 8.6% in its latest quarter.

You may also be interested in...



Prestige Consumer Feels ‘5-Ounce Hammer' From Pandemic Headwinds

Prestige hasn’t totally escaped supply chain disruptions caused by shutdowns during the pandemic but it’s relieved to report a smaller impact than most consumer-packaged goods marketers. Slower cough/cold OTC sales also don’t slow its results.

Prestige Consumer Healthcare Grows International Sales 8%, Citing Hydralyte Expansion

Prestige Consumer Healthcare’s Hydralyte sales grew in excess of 20% fiscal year-to-date in key market Australia, reflecting PCH’s work to expand the brand’s appeal from a vomiting and diarrhea treatment to a sports and general hydration drink. Hydralyte is PCH’s biggest brand in Australia where the name is “synonymous with oral hydration,” company leadership says.

OTC Decisions Tracker: Dr Reddys NRT Lozenge Approved, Prilosec OTC And Monistat Packaging Revised

HBW Insight introduces an ongoing feature with information on decisions by FDA on NDAs and ANDA for nonprescription drugs and on sNDAs for label and package changes for approved OTC products. Dr Reddys Laboratories' clearance to launch OTC nicotine replacement therapy lozenges in the US and revisions to Prilosec OTC and Monistat packaging were among FDA's s OTC-related decisions in January.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel